• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 319
  • 308
  • 45
  • 19
  • 18
  • 17
  • 11
  • 10
  • 10
  • 5
  • 3
  • 2
  • 2
  • 2
  • 1
  • Tagged with
  • 817
  • 497
  • 475
  • 301
  • 253
  • 166
  • 65
  • 63
  • 59
  • 52
  • 52
  • 50
  • 49
  • 41
  • 40
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
341

Establishing Clinical Variables towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis

Chalhoub, Nathalie E. 25 June 2019 (has links)
No description available.
342

Identification des cibles antigéniques d'origine mitochondriale, reconnues par les autoanticorps dans le lupus érythémateux disséminé

Becker, Yann 29 March 2022 (has links)
Mitochondria are intracellular organelles in control of numerous biological functions (e.g.,from energy supply to steroidogenesis and programmed cell death by apoptosis). Evolutively, mitochondria are considered as derived from the endosymbiosis between an α-proteobacterium and a primitive eukaryotic cell. Due to its origin, the organelle displays prokaryotic motifs such as a circular double-stranded hypomethylated DNA (i.e., mtDNA) and N-formylated peptides. Intact or damaged mitochondria, as well as mitochondrial components may be extruded in the extracellular space upon cell activation or death. These features, as well as several biomolecules localized within the mitochondrion (e.g.,ATP, cytochrome C) are able to be recognized by the innate immune system as mitochondrial damage-associated molecular patterns, thus eliciting a proinflammatory response. A humoral immune response comprising anti-mitochondrial antibodies (AMA) is also described in various autoimmune conditions, such as AMA-M2 in primary biliary cirrhosis (i.e., PBC). Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the alternance of flares and phases of remission, due to the deposition of antibody-antigen scaffolds (i.e., immune complexes) within tissues, leading to various clinical manifestations (e.g., neuropsychiatric, hematological or dermatological disorders). The antiphospholipid syndrome (i.e., APS) is an autoimmune disease, with thromboembolic and/or obstetrical manifestations, that can either be found alone or along with SLE. While the immunogenicity of cardiolipin (i.e., a phospholipid uniquely synthetized by mitochondria In humans) is well described in SLE and APS (i.e., anticardiolipins), mitochondrial proteins targeted by autoantibodies are still poorly known. The present doctoral thesis follows my masters' project during which I developed ELISAs allowing for the detection of AMA targeting intact mitochondria (i.e., AwMA) or mtDNA (i.e., AmtDNA)¹. The present project aims aims to characterize the mitochondrial immunogenicity in SLE and APS. The University of Toronto Lupus Clinic cohort comprise sera from patients with SLE or APS (n=175 and n=12 respectively). AwMA and AmtDNA levels were assessed in these samples, as well as in sera from healthy volunteers (n=43) or patients with PBC (n=12). I observed that all patients had increased AwMA, compared to healthy individuals. AmtDNA were only increased in SLE patients and were associated with increased past reports of lupus nephritis (p=0.01). These results were published in March 2019 in Scientific Reports². During the acquisition of these data, I observed that patients' sera also presented immunoreactivity against mitochondrial RNA (i.e., mtRNA). I thus adapted my assays to detect autoantibodies against mtRNA (i.e., AmtRNA), and assessed their levels in sera from patients includes in the systemic autoimmune rheumatic disease biobank and data repository (i.e., SARD-BDB. Healthy:n=30, SLE:n=87). AmtRNA were significantly elevated in SLE (IgG: p<0.0001, IgM:p=0.0493). Surprisingly, AmtRNA-IgG were associated with decreased reports of past lupus nephritis (p=0.03) and carotid plaque (p=0.04). This study was published in Frontiers in Immunology in May 2019³. As each AMA assessed displayed biostatistical associations with antiphospholipids, I replicated these protocols, using sera from patients with APS, included in the SARD-BDB (n=27). AmtRNA (IgG:p=0.0005, IgM:p=0.01) and AmtDNA-IgM were increased in APS (p=0.009). However, only AmtDNA-IgM were associated with reports of arterial thromboses (p=0.047). This pilot study was published in Lupus in August 2020⁴. In a a recent study, accepted in Arthritis & Rheumatology in January 2022⁵, we identified by mass spectrometry 1345 proteins associated with AwMA, 431 of with were assigned to the mitochondrial proteome. These results allowed to identify two candidates: C1qBP and Mfn-1. IgGs to C1qBP were increased in (p=0.0167) and associated with positivity to the lupus anticoagulant (p=0.049) in SLE. IgGs against Mfn-1 are interesting candidates for the prediction of the disease (p=0.0052) and are associated with positivity to antiphospholipids (p=0.011) and antibodies against double-stranded DNA (p = 0.0005). These results highlight the immunogenicity of the organelle in SLE and APS. Mitochondrial antigens are interesting candidates for the development of novel clinical assays allowing improved prognosis, diagnosis, or disease stratification, ultimately contributing to the improvement of medical care for people with autoimmune conditions. / Les mitochondries sont des organelles intracellulaires considérées comme issues de l'endosymbiose entre une α-protéobactérie et une cellule eucaryote primitive. L'organelle exprime ainsi des motifs moléculaires en lien avec son origine procaryote tels qu'un ADN hypométhylés (i.e., mtDNA) ou des peptides N-formylés. Des mitochondries ou bien des composantes mitochondriales pourront être libérées dans le milieu extracellulaire lors de différents évènements d'activation ou de mort cellulaire. Ces caractéristiques ainsi que certaines biomolécules, spécifiquement localisées dans la mitochondrie (e.g.,ATP, cytochrome C) auront la capacité d'être reconnues comme des motifs de dangers et de stimuler une réponse proinflammatoire de la part des cellules du système immunitaire inné. Une réponse humorale constituée d'anticorps anti-mitochondriaux (AMA) est connue dans différents troubles auto-immuns tels que les AMA-M2 dans la cirrhose biliaire primitive (PBC). Le lupus érythémateux disséminé (SLE) est une maladie auto-immune caractérisée par une succession de phases d'exacerbation et de rémission dues au dépôt d'enchevêtrements d'autoanticorps et de leurs antigènes dans les tissus, aboutissant à une grande variété de manifestations cliniques (e.g.,manifestations neuropsychiatriques, hématologiques, dermatologiques). Le syndrome des antiphospholipides (APS) est une maladie qui peut être distincte ou associée au SLE et présente des manifestations thromboemboliques et/ou obstétriques. Bien que l'immunogénicité de la cardiolipine (i.e., phospholipide uniquement synthétisée dans la mitochondrie chez l'humain) soit connue dans le cadre du SLE et de l'APS (i.e., anticardiolipines), l'antigénicité des protéines mitochondriales reste encore méconnue. Cette thèse de doctorat fait suite à mes travaux de maîtrise au cours desquels, j'ai développé des ELISAs permettant de mesurer des niveaux des IgGs dirigés contre les mitochondries intactes (i.e., AwMA) et le mtDNA (i.e., AmtDNA)¹. Mon projet de thèse vise à caractériser l'immunogénicité mitochondriale dans l'auto-immunité. La cohorte de la University of Toronto Lupus Clinic regroupe des échantillons d'échantillons de séra de patients souffrant de SLE ou d'APS (n=175 et n=12, respectivement). Les AwMA, et AmtDNA ont été mesurés au sein de ces échantillons ainsi que d'échantillons de volontaires sains (n=43) et de donneurs souffrant de PBC (n=12). Les patients souffrant des trois conditions présentaient une augmentation significative des AwMA par rapport aux contrôles sains. Les AmtDNA, uniquement augmentés chez les patients SLE (p=0.0004) ont été associés à des antécédents accrus de néphrite lupique (p=0.01). Ces résultats ont été publiés en mars 2019 dans le journal Scientific Reports² . Durant ces mesures, j'ai observé que les séra de patients présentaient aussi une immunoréactivité dirigée contre l'ARN mitochondrial (mtRNA). J'ai, par la suite, adapté mes tests pour détecter les AMA dirigés contre le mtRNA (i.e., AmtRNA) et les ai mesurés à l'aide de séra inclus dans la cohorte des maladies rhumatismales auto-immunes systémiques (MRAS. Sains:n=30, SLE:n=87). Les d'AmtRNA sont significativement élevés dans le SLE (IgG:p<0.0001 , IgM:p=0.0493). De façon surprenante, les AmtRNA-IgG sont associés avec des historiques réduits de néphrite lupique (p=0.03) et de plaque carotidienne (p=0.04). Ces travaux ont été publiés dans le journal Frontiers in Immunology en mai 2019³. L'ensemble des AMA mesurés présentant des associations biostatistiques avec différents anticorps antiphospholipides. J'ai répliqué mon protocole sur des échantillons de patients souffrant d'APS, inclus dans la cohorte MRAS (n=27). Les AmtRNA (IgG:p=0.0005, IgM:p=0.01) et les AmtDNA-IgM sont augmentés dans l'APS (p=0.009). Seuls les AmtRNA-IgM sont associées avec une diminution des antécédents de thromboses artérielles (p=0.047). Ce projet a fait l'objet d'un article, publié dans Lupus en aout 2020⁴. Dans une autre étude, acceptée dans le journal Arthritis & Rheumatology en janvier 2022⁵, nous avons identifié, par spectrométrie de masse, 1345 protéines associées aux AwMA dont 431 sont associées avec le protéome mitochondrial. Ces résultats m'ont permis d'identifier deux candidats d'intérêts : C1qBP et Mfn-1. Les anti-C1qBP sont significativement augmentés chez les patients lupiques (p=0.0167) et sont associés avec la positivité pour l'anticoagulant lupique (p=0.049). Les anti-Mfn1 constituent de potentiels candidats pour prédire la maladie (p=0.0052). Ils sont, par ailleurs, associés avec la positivité aux antiphospholipides (p=0.011) et aux anti-ADN double brins (p=0.0005). Ces résultats soulignent l'immunogénicité de la mitochondrie dans le SLE et l'APS. Les AMA et leurs cibles constituent de nouvelles avenues d'intérêt dans la mise au point de nouveaux tests cliniques permettant le diagnostic, le pronostic ou la classification de la maladie afin d'améliorer la prise en charge des patients lupiques.
343

Effect of Impaired T Cell Receptor Signaling on the Gut Microbiota in a Mouse Model of Systemic Autoimmunity / T細胞受容体シグナルの障害が腸内細菌叢と全身性自己免疫に及ぼす影響

Taguchi, Mirei 23 March 2023 (has links)
京都大学 / 新制・論文博士 / 博士(医学) / 乙第13536号 / 論医博第2276号 / 新制||医||1065(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 河本 宏, 教授 妹尾 浩, 教授 中川 一路 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM
344

Identifying a Link Between Uranium Exposure and Systemic Lupus Erythematosus in a Community Living near a Uranium Plant

Lu, Pai-Yue 17 October 2013 (has links)
No description available.
345

Pediatric Lupus Transitional Care: An Interactive Experience. A Fly on the Wall: Youth and Young Adult Perspectives

Johnson, Kiana 01 January 2015 (has links)
No description available.
346

Perivascular fibroblast activation states in human skin diseases

Barron, Alexander Michael Shuford 30 January 2020 (has links)
The perivascular adventitia (PA) senses and responds to injuries in blood vessels and the tissues they feed. Cells in the PA form the outermost vascular layer, joining the circulatory system to other organs. Housing hematopoietic, mesenchymal and neuronal cells allows flexible adventitial responses to diverse perturbations. However, the PA response can also be pathogenic. Thickening of the adventitia may drive ischemia and hypertension. It can also be a niche for local lymphocyte priming in diseases such as idiopathic pulmonary arterial hypertension. Despite their importance, PA contributions to skin diseases were understudied. The hypothesis that contrasting two cutaneous diseases, scleroderma and discoid lupus erythematosus (DLE), would illuminate discrete PA alterations was explored. Vascular changes are prominent, but distinct, in both diseases. Studying perivascular adventitial changes in these diseases may yield insights into both dermal and vascular pathologies. PA fibroblasts in healthy human skin were phenotypically distinct from the surrounding dermal fibroblasts. In both scleroderma and DLE, PA fibroblasts expanded and expressed surface markers not observed in healthy skin including vascular cell adhesion molecule 1 (VCAM1), podoplanin (PDPN) and the p75 low affinity nerve growth factor receptor (NGFR). Elaborated networks of PA fibroblasts in DLE expressed VCAM1 and enmeshed dense, T cell-rich infiltrates. Transcriptional analyses indicated positive correlations between VCAM1, T cell chemoattractants and interleukin (IL)-15, which promotes their survival. Activated PA fibroblasts in DLE likely create a supportive niche for T cells infiltrating the skin. In contrast, enlarged PA fibroblast networks in scleroderma expressed NGFR in the absence of leukocyte infiltrates. This PA fibroblast phenotype was shared among reparative and pathologic scarring, and four dermal tumors. NGFR is a mesenchymal stem cell (MSC) marker, and expanded NGFR+ mesenchymal cells were immediately adjacent to cluster of differentiation (CD)34+ and CD73+ PA MSC. Expression of NGFR by PA fibroblasts is likely associated with reparative responses. Different stimuli induced VCAM1 and NGFR on cultured human dermal fibroblasts, supporting these as discrete activation states. In conclusion, these studies demonstrated the responsive and plastic nature of human dermal PA mesenchymal cells, and pointed to connections with vascular alterations in skin diseases.
347

GENE BY ENVIRONMENT INTERACTION IN LINKAGE ANALYSIS: THE EFFECTS OF BODY MASS INDEX ON SYSTEMIC LUPUS ERYTHEMATOSUS

Goodloe, Robert James, Jr 05 April 2008 (has links)
No description available.
348

Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus

Vega-Fernandez, Patricia 13 October 2014 (has links)
No description available.
349

Pain, Fatigue and Psychological Impact on Health-related Quality of Life in Childhood-onset Lupus

Jones, Jordan T. 22 June 2015 (has links)
No description available.
350

Urine S100 Proteins as Potential Biomarkers of Lupus Nephritis Activity

Turnier, Jessica L., M.D. 27 October 2017 (has links)
No description available.

Page generated in 0.0354 seconds